Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Position Decreased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lessened its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 634,613 shares of the medical equipment provider’s stock after selling 10,619 shares during the period. Envestnet Asset Management Inc. owned 0.18% of Intuitive Surgical worth $282,308,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ISRG. Norges Bank bought a new position in Intuitive Surgical in the 4th quarter worth about $1,313,238,000. Capital Research Global Investors acquired a new position in Intuitive Surgical in the 1st quarter valued at $374,390,000. Coatue Management LLC grew its stake in Intuitive Surgical by 65.7% in the 4th quarter. Coatue Management LLC now owns 1,301,595 shares of the medical equipment provider’s stock valued at $439,106,000 after buying an additional 516,054 shares during the last quarter. Vanguard Group Inc. grew its stake in Intuitive Surgical by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after buying an additional 493,126 shares during the last quarter. Finally, Edgewood Management LLC grew its stake in Intuitive Surgical by 7.9% in the 4th quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after buying an additional 374,667 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 238 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $477.50, for a total value of $113,645.00. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at $2,629,115. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the transaction, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Robert Desantis sold 238 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $477.50, for a total transaction of $113,645.00. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,629,115. The disclosure for this sale can be found here. Insiders have sold a total of 50,555 shares of company stock worth $24,267,737 over the last ninety days. Corporate insiders own 0.90% of the company’s stock.

Analyst Upgrades and Downgrades

ISRG has been the topic of a number of research analyst reports. Robert W. Baird raised their target price on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research note on Friday, July 19th. Barclays raised their target price on shares of Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research note on Thursday, July 18th. Piper Sandler raised their target price on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Citigroup raised their target price on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Finally, Stifel Nicolaus increased their price target on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a report on Friday, July 19th. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $489.86 on Friday. The firm’s 50-day simple moving average is $463.74 and its 200-day simple moving average is $421.80. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $496.18. The firm has a market cap of $173.75 billion, a P/E ratio of 88.42, a price-to-earnings-growth ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm’s revenue was up 14.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.18 EPS. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.